SANTA CLARA, Calif.--Researchers looking to quickly and confidently identify expression biomarkers using highly challenging clinical research samples now have access to Thermo Fisher Scientific’s new Clariom Pico assays—the next generation family of transcriptome profiling tools designed to provide a fast and simple path to discovery.

The two Clariom brand of assays (Clariom D Pico and Clariom S Pico) are designed primarily for translational researchers to accelerate the discovery and validation of complex biomarker signatures derived from both coding and non-coding RNA across the whole transcriptome. Based on industry-leading microarray technology, the Clariom Pico assay designs include the most up to date content curated from the largest number of public sequence databases, including RefSeq, NONCODE, Ensembl, VEGA, lncRNAWiki, and RNA Central, among several others, so that scientists can remain confident in their discoveries.

For a deep view of the transcriptome, Clariom D Pico assays allow rapid discovery of coding and non-coding genes, exons, and splicing events, including rare transcripts, expanding the potential to find novel biomarkers missed by alternative techniques. For researchers interested in a gene-level view of all well-annotated genes across the transcriptome, Clariom S Pico assays enable scientists to quickly and easily identify important expression changes in genes and pathways.

“We chose Clariom D Pico Assay because this platform enables us to profile the transcriptome, including lncRNA, of invaluable clinical research samples despite low quality RNA and low total quantity at a fraction of the cost compared to RNA-Seq,” said Aritro Nath, Ph.D., postdoctoral scholar in the Department of Medicine – Hematology/Oncology at the University of Chicago.

The Clariom Pico assays can extract robust data from as little as 100 pg of total RNA from a wide range of common and challenging sample types, including formalin-fixed paraffin-embedded (FFPE) tissues and whole blood without the need for globin mRNA reduction or rRNA removal. When paired with Thermo Fisher’s highly intuitive Transcriptome Analysis Console (TAC) Software, scientists can independently go from sample to insights in three days. Made for the biologist, TAC Software is provided free of charge to customers so they can spend their time and resources translating results into meaningful publications rather than analyzing data.

“We know scientists are in need of faster, simpler and more cost-effective tools to find biomarkers. They do not want to trade their ability to identify important expression changes for the cost or ease of analysis,” said Laurent Bellon, Ph.D., vice president and general manager of Microarrays at Thermo Fisher Scientific. “In response to this need, we have developed extremely sophisticated arrays that include the most content available on the market today for our customers. We also evolved our target preparation chemistry to allow researchers to use sample types most important and readily available to them.”

To learn more about Clariom assays, visit www.affymetrix.com/clariom.

For research use only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific 
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

Contact: